Author

Raman Rajagopal

University of DelhiORCID 0000-0002-1476-8497Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:simulation· 2 Approach:statistical model· 2 Organism:bacteria (other)· 1 Organism:human· 1 Assay:protein structure· 1

Frequent Co-Authors

Amisha PandaiD· 2 shared Anannya BandyopadhyayiD· 2 shared Jahnvi KapooriD· 2 shared Sanjiv KumariD· 2 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

4 top collaborators · 6 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioinformatics

Amisha PandaORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

BioinformaticsbioRxivPreprintJul 26, 2026

First Molecular-Level Model of the Chlamydia trachomatis Injectisome and Targeting CdsN ATPase Oligomerization for Antivirulence Therapy

Amisha Panda, Jahnvi Kapoor, Raman Rajagopal…·Anannya Bandyopadhyay

The paper models the molecular structure of Chlamydia trachomatis T3SS and identifies FDA-approved drugs that target CdsN ATPase oligomerization for antivirulence therapy.

DOI 10.64898/2026.05.06.723290

humanstatistical model

𝕏 PostBluesky

BioinformaticsJournal of Chemical Information and ModelingPeer-reviewedJun 10, 2026

Structural Characterization of the Type IV Secretion System in Brucella melitensis for Virtual Screening-Based Therapeutic Targeting

Jahnvi Kapoor, Amisha Panda, Raman Rajagopal…·Anannya Bandyopadhyay

This study models the T4SS structure of Brucella melitensis and identifies three FDA-approved drugs that could target the system for anti-virulence therapy.

1 citationtop 4%

bacteria (other)protein structure

𝕏 PostBluesky